Patents by Inventor Jay Larrow

Jay Larrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS
    Publication number: 20150166563
    Abstract: The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 18, 2015
    Applicant: NOVARTIS AG
    Inventors: Sejal Patel, Justin Mao, Qian Liu, Rui Zheng, Tyler Harrison, Rohit Duvadie, Xin Chen, Frederic Zecri, Jay Larrow, Xuchun Zheng, Yizong Zhou, Jiong Ye, Yiping Ding, Yu Gai
  • Cyclic bridgehead ether DGAT1 inhibitors
    Patent number: 8993619
    Abstract: The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: March 31, 2015
    Assignee: Novartis AG
    Inventors: Sejal Patel, Justin Mao, Qian Liu, Rui Zheng, Tyler Harrison, Rohit Duvadie, Xin Chen, Frederic Zecri, Jay Larrow, Xuchun Zheng, Yizong Zhou, Jiong Ye, Yiping Ding, Yu Gai
  • CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS
    Publication number: 20130289058
    Abstract: The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.
    Type: Application
    Filed: April 26, 2013
    Publication date: October 31, 2013
    Inventors: Sejal Patel, Justin Mao, Qian Lui, Rui Zheng, Tyler Harrison, Rohit Duvadie, Xin Chen, Frederic Zecri, Jay Larrow, Xuchun Zheng, Yizong Zhou, Jiong Ye, Yiping Ding, Yu Gai
  • Process for making substituted 2-amino-thiazolones
    Patent number: 8541593
    Abstract: The present invention relates to methods of making compounds that inhibit 11-hydroxysteroid dehydrogenase type 1 enzyme (11-HSD1). One method comprises (a) contacting a compound of formula (II) sequentially with a chiral base in the presence of an amine, and an alkylating agent R3-LG, (b) contacting the product of (a) with an acid to form a salt, and (c) reacting the salt with a base to form the compound of formula (I), wherein Z, R1, R2, and R3 are defined herein.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: September 24, 2013
    Assignee: Amgen Inc.
    Inventors: George A. Moniz, Matthew J. Frizzle, Charles Bernard, Michael Martinelli, Margaret M. Faul, Roger Nani, Jay Larrow
  • Process for making substituted 2-amino-thiazolones
    Patent number: 8536345
    Abstract: The present invention relates to methods of making compounds that inhibit 11-?-hydroxysteroid dehydrogenase type 1 enzyme (11-? HSD1). One method comprises (a) contacting a compound of formula (II) with a chiral base, deprotonating agent, and an alkylating agent R3-LG, (b) contacting the product of (a) with an acid to form a salt, and (c) reacting the salt with a base to form the compound of formula (I); wherein Z, R1, R2, and R3 are defined herein.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: September 17, 2013
    Assignee: Amgen Inc.
    Inventors: George A. Moniz, Matthew J. Frizzle, Charles Bernard, Michael Martinelli, Margaret Faul, Jay Larrow, Karl B. Hansen, Liane Klingensmith
  • PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES
    Publication number: 20110160463
    Abstract: The present invention relates to methods of making compounds that inhibit 11-?-hydroxysteroid dehydrogenase type 1 enzyme (11-? HSD1). One method comprises (a) contacting a compound of formula (II) with a chiral base, deprotonating agent, and an alkylating agent R3-LG, (b) contacting the product of (a) with an acid to form a salt, and (c) reacting the salt with a base to form the compound of formula (I); wherein Z, R1, R2, and R3 are defined herein.
    Type: Application
    Filed: June 16, 2009
    Publication date: June 30, 2011
    Inventors: George A. Moniz, Matthew J. Frizzle, Charles Bernard, Michael Martinelli, Margaret Faul, Jay Larrow, Karl B. Hansen, Liane Klingensmith
  • PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES
    Publication number: 20100280255
    Abstract: The present invention relates to methods of making compounds that inhibit 11-hydroxysteroid dehydrogenase type 1 enzyme (11-HSD1). One method comprises (a) contacting a compound of formula (II) sequentially with a chiral base in the presence of an amine, and an alkylating agent R3-LG, (b) contacting the product of (a) with an acid to form a salt, and (c) reacting the salt with a base to form the compound of formula (I), wherein Z, R1, R2, and R3 are defined herein.
    Type: Application
    Filed: June 20, 2008
    Publication date: November 4, 2010
    Applicant: AMGEN INC.
    Inventors: George A. Moniz, Matthew J. Frizzle, Charles Bernard, Michael Martinelli, Margaret Faul, Roger Nani, Jay Larrow
  • Benzomorpholine derivatives and methods of use
    Patent number: 7795254
    Abstract: Selected benzomorpholine compounds, including 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(5 -methyl-3-isoxazolyl)-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide, are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: September 14, 2010
    Assignee: Amgen Inc.
    Inventors: Jean-Christophe Harmange, Matthew W. Martin, Yohannes Teffera, Raju Subramanian, Ryan White, Roger Zanon, Jay Larrow, Joseph F. Payack, Mina Dilmeghani Seran
  • Benzomorpholine derivatives and methods of use
    Publication number: 20090149454
    Abstract: Selected benzomorpholine compounds are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: October 28, 2008
    Publication date: June 11, 2009
    Applicant: Amgen Inc.
    Inventors: Jean-Christophe Harmange, Matthew W. Martin, Yohannes Teffera, Raju Subramanian, Ryan White, Roger Zanon, Jay Larrow, Joseph F. Payack, Mina Dilmeghani Seran
  • Hydrolytic kinetic resolution of cyclic substrates
    Publication number: 20050187392
    Abstract: The present invention relates to a process for stereoselective or regioselective chemical synthesis which generally comprises reacting a nucleophile and a chiral or prochiral cyclic substrate in the presence of a non-racemic, chiral catalyst to produce a stereoisomerically- and/or regioisomerically-enriched product. The present invention also relates to hydrolytic kinetic resolutions of racemic and diastereomeric mixtures of epoxides.
    Type: Application
    Filed: January 5, 2005
    Publication date: August 25, 2005
    Applicant: Harvard University
    Inventors: Eric Jacobsen, Makoto Tokunaga, Jay Larrow